<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Operations Buzz</title>
	<atom:link href="http://operationsbuzz.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://operationsbuzz.com</link>
	<description>A resource on running smart &#38; sustainable operations</description>
	<lastBuildDate>Fri, 09 Dec 2016 20:27:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.9.7</generator>
	<item>
		<title>Taking Stock of Carbon Footprints: A Visual Journey</title>
		<link>http://operationsbuzz.com/2013/06/carbonfootprints/</link>
		<comments>http://operationsbuzz.com/2013/06/carbonfootprints/#respond</comments>
		<pubDate>Fri, 28 Jun 2013 14:49:10 +0000</pubDate>
		<dc:creator><![CDATA[Ram Ganeshan]]></dc:creator>
				<category><![CDATA[Field Notes]]></category>
		<category><![CDATA[Sustainability]]></category>
		<category><![CDATA[carbon]]></category>
		<category><![CDATA[footprint]]></category>
		<category><![CDATA[visual]]></category>

		<guid isPermaLink="false">http://operationsbuzz.com/?p=368</guid>
		<description><![CDATA[President Obama, on June 25<sup>th</sup>, <a href="http://www.whitehouse.gov/share/climate-action-plan">laying out America’s climate policy</a> for the future said:

“So the question now is whether we will have the courage to act before it’s too late. And how we answer will have a profound impact on the world that we leave behind not just to you, but to your children and to your grandchildren. As a President, as a father, and as an American, I’m here to say we need to act.”

This post is about taking stock of carbon footprint of things big and small – countries, cities, industrial sectors, firms, products, and supply chains. Through an interactive visual, you can get a sense of carbon footprints of things big or small.

Enjoy!]]></description>
				<content:encoded><![CDATA[<p>President Obama, on June 25<sup>th</sup>, <a href="http://www.whitehouse.gov/share/climate-action-plan">laying out America’s climate policy</a> for the future said:</p>
<p>“So the question now is whether we will have the courage to act before it’s too late. And how we answer will have a profound impact on the world that we leave behind not just to you, but to your children and to your grandchildren. As a President, as a father, and as an American, I’m here to say we need to act.”</p>
<p>This post is about taking stock of carbon footprint of things big and small – countries, cities, industrial sectors, firms, products, and supply chains. Through an interactive visual, you can get a sense of carbon footprints of things big or small.</p>
<p>Enjoy!</p>
<p>Since the 1750s, atmospheric concentrations of carbon dioxide have risen from about 280 parts per million and recently crossed the <a href="http://blogs.scientificamerican.com/observations/2013/05/09/400-ppm-carbon-dioxide-in-the-atmosphere-reaches-prehistoric-levels/">400 parts per million (ppm) barrier</a>. Green House Gas (GHG) emissions have led to a 0.6 degree Celsius increase in the global average surface temperature since 1900. If the current trends in emissions continue, the <a href="http://www.ipcc.ch">Intergovernmental Panel on Climate Change (IPCC)</a> estimates that global temperatures will rise a further 1.4 degrees to 5.8 degrees Celsius by 2100. Scientists agree that such increases will have disastrous effects &#8211; disrupting ecosystems (about 30% of plant and animal species will face extinction); increasing and intensifying environmental and climate disasters; endangering the world’s food supply; and causing widespread health issues. The consequences will negatively impact a large portion of the world’s population, especially in impoverished countries.</p>
<p>Yes, it is time to act.</p>
<p>There is widespread agreement today to keep the global average temperature from increasing by more than two degrees Celsius above pre-industrial levels. Scientists estimate that total emissions going forward should not exceed <a href="http://www.rollingstone.com/politics/news/global-warmings-terrifying-new-math-20120719">565 billion tons</a> by mid-century. The total GHG emissions in 2012 were in the order of 31.6 billion tons, and trends indicate that global emissions are increasing by about three percent every year. At this rate, it will take just over 15 years to hit the 565 billion ton number. Reversing this alarming trend will involve concerted carbon management efforts at all levels – countries, cities, local governments, corporations and individuals. My intent is to give you a visual journey of the carbon footprints of various entities – from countries and cities to products and their component parts. Following the adage of “what gets measured gets managed,” carbon footprints can help identify hotspots where action can be taken to mitigate emissions.</p>
<p><b>Footprint of Countries and Cities</b></p>
<p>A “carbon footprint” of an entity – a country, city, event, firm, product or service &#8211; is the total amount of greenhouse gas emissions (GHG) it produces. Greenhouse gases other than carbon dioxide (CO<sub>2</sub>), such as methane, nitrous oxide, sulfur hexafluoride and others are converted to their “CO<sub>2</sub> equivalent” (CO<sub>2</sub>e) weight so that a single number can represent the environmental impact of the product.</p>
<p>The accompanying visual (see the “Countries &amp; Cites” tab) shows the footprint of the 20 largest GHG emitting countries in 2012. The <a href="http://unfccc.int/kyoto_protocol/items/2830.php">Kyoto protocol</a>, signed in 1990 under the “common but differentiated responsibility” principle, set binding targets for 37 industrialized countries (also called “Annex I”) for reducing GHG emissions by the end of 2012. The United States did not ratify the Kyoto protocol. China, India and Brazil &#8211; as developing economies &#8211; were exempt from emission reduction targets. Attempts to extend the Kyoto treaty beyond 2012 have thus far failed. However, in 2009, the <a href="http://unfccc.int/documentation/documents/advanced_search/items/6911.php?priref=600005735">Copenhagen Accord</a> endorsed “the scientific view that the increase in global temperature should be below two degrees Celsius” and that Annex I countries will “commit to economy-wide emissions targets for 2020.” The Accord also recognized that developing nations would have to “implement mitigation actions,” report their emissions and subject these to verification.</p>
<p>Although not legally binding, several countries have proposed <a href="http://unfccc.int/meetings/cop_15/copenhagen_accord/items/5262.php">reduction targets</a> in connection with the Copenhagen Accord. Compared to 1990 levels, the EU has proposed a target reduction of 20-30%, Japan by 25%, and Russia by 15-25%. President Obama’s plan proposes a 17% cut by 2020 compared to 2005 levels. China has proposed a cut of 40-45%; and India a cut of 20-25% on emission intensity (GHG per unit of GDP) by 2020 compared to 2005 levels. China and India’s measures do not ensure a reduction in absolute emissions – only that emissions will grow slower than GDP growth.</p>
<p>Cities, as the hub of social and economic activity, are both significant contributors of GHG emissions and highly vulnerable to climate change. City governments oversee infrastructure, host and promote businesses and provide services for their citizens.</p>
<p>Cities have a major role to play in GHG mitigation. First, city governments and services can have a substantial carbon footprint. For example, New York City government operations account for 3.47 million metric tons of CO<sub>2</sub>e annually. Tokyo’s city government emissions are 2.06 million metric tons annually. Using renewable energy, expanding and improving the efficiency of public transport, retrofitting public buildings and street lighting, managing waste streams and increasing green spaces all reduce the footprint and enable a better quality of life. Second, cities have a significant impact on how their citizens live and how corporations conduct business. Engaging citizens and businesses through incentives and joint partnerships will galvanize cities to become climate neutral. Portland and Seattle (US), Toronto (Canada) and Yokohama (Japan) have targeted an 80% decrease in CO<sub>2</sub>e emissions by 2050 over 1990 levels. Rotterdam (Netherlands) has pledged a cut in emissions by 50% and London (UK) has proposed a cut of 60% in emissions by 2025 over 1990 levels.</p>
<p>more after the graphic&#8230;</p>
<p><script type="text/javascript" src="http://public.tableausoftware.com/javascripts/api/viz_v1.js"></script></p>
<div class="tableauPlaceholder" style="width:900px; height:593px;"><noscript><a href="#"><img alt=" " src="http:&#47;&#47;public.tableausoftware.com&#47;static&#47;images&#47;Ca&#47;CarbonFootprintScopes&#47;CountriesandCities&#47;1_rss.png" style="border: none" /></a></noscript><object class="tableauViz" width="900" height="593" style="display:none;"><param name="host_url" value="http%3A%2F%2Fpublic.tableausoftware.com%2F" /><param name="site_root" value="" /><param name="name" value="CarbonFootprintScopes&#47;CountriesandCities" /><param name="tabs" value="yes" /><param name="toolbar" value="yes" /><param name="static_image" value="http:&#47;&#47;public.tableausoftware.com&#47;static&#47;images&#47;Ca&#47;CarbonFootprintScopes&#47;CountriesandCities&#47;1.png" /><param name="animate_transition" value="yes" /><param name="display_static_image" value="yes" /><param name="display_spinner" value="yes" /><param name="display_overlay" value="yes" /><param name="display_count" value="yes" /></object></div>
<div style="width:1375px;height:22px;padding:0px 10px 0px 0px;color:black;font:normal 8pt verdana,helvetica,arial,sans-serif;">
<div style="float:right; padding-right:8px;"><a href="http://www.tableausoftware.com/public/about-tableau-products?ref=http://public.tableausoftware.com/views/CarbonFootprintScopes/CountriesandCities" target="_blank">Learn About Tableau</a></div>
</div>
<p><b>Industrial sector, Firm, and Product Footprints</b></p>
<p>Businesses are responsible for 20-25% of the world’s GHG emissions.  Their emissions are a result of their production processes and facilities, the resources they consume, extraction and processing of relevant raw materials in supplier operations and the impact of their product or service on their customers.</p>
<p>Firms are increasingly accessing the risk and opportunities of climate change and integrating it into the overall business strategy. In the latest survey by the non-profit <a href="https://www.cdproject.net/en-US/Pages/HomePage.aspx">Carbon Disclosure Project</a> of the top 500 global firms, 48% said that they integrate risks and opportunities of climate change into their planning and 65% of them indicated that they had GHG emission mitigation targets. The major reasons for reducing GHG emissions include the increased ability to market new low-carbon products, compliance to existing and anticipated laws, and to increase efficiency while reducing disruptions in the supply chain.</p>
<p>There are multiple standards available to companies for accounting their GHG emissions. <a href="http://www.ghgprotocol.org">The Greenhouse Gas Protocol</a> (GHG Protocol), developed in partnership with the <a href="http://www.wri.org">World Resources Institute</a> (WRI) and the <a href="http://www.wbcsd.org/home.aspx">World Business Council for Sustainable Development</a> (WBCSD), is the most widely used standard. It provides businesses a consistent, and verifiable way to account for their GHG emissions. The GHG Protocol specifies three types of emissions called “scopes.” Scope 1 emissions are a result of all company operations – production processes, waste streams, facilities, and employees. Scope 2 is emissions from purchased electricity, and Scope 3 is emissions associated with the supply chain. This includes related emissions from suppliers who handle product components; and the emissions from downstream distribution, use, and end-of-life management of the product/service.</p>
<p>The scope information gives an insight into appropriate strategies to reduce emissions. Scope 3, not surprisingly, for the Energy sector (see the “Industrial Sectors” tab) is almost an order of magnitude larger than the sum of scope 1 and scope 2. While Oil &amp; Gas exploration, drilling, refining, transportation, and storage are responsible for large GHG emissions, the use of oil &amp; gas by other industrial sectors, residences, automobiles, trains, and planes are responsible for most of the emissions in this sector. The solution to reduce emissions in this industry is obviously complex – a national energy policy (President Obama’s policy will move away from coal towards natural gas and this will no doubt help reduce GHGs), fuel efficiency standards, urban planning and transportation all have important roles to play in addition to the firms in the sector.</p>
<p><b>Firm Snapshot: Apple Inc.</b></p>
<p><a href="http://www.apple.com">Apple Inc.</a> designs, manufactures and sells a wide range of electronic devices, software, services, and third-party digital content and applications via its retail, iTunes, and App stores.</p>
<p>To manufacture its electronics devices, Apple sources components from all over the world, subcontracts production and assembly primarily in Asia, and sells in its own retail outlets in addition to several over distribution channels (See my post on the <a href="http://operationsbuzz.com/2010/11/the-iphone-4-supply-chain/">Apple iPhone 4 Supply Chain</a>). The “Company” tab shows the scope 1, 2, and 3 breakdown for Apple. Scope1 and 2 are primarily from its facilities. Scope 3 emissions, meanwhile, is more than 50 times the sum of the scope 1 and 2 combined. This includes among others, the emissions from supplier operations, production, transportation, product use, and recycling. The <a href="http://www.apple.com/environment/">two biggest sources</a> of emissions are production and product use.</p>
<p>Apple’s GHG reductions in production includes reducing material use in devices and in packaging, elimination of certain hazardous materials, and designing the product with appropriate materials such as Aluminum and glass so they can be recycled at end of life. The design also involves energy efficient components and it’s monitoring via software so the emissions during product use are reduced. Apple has increased its reliance on renewable energy by 200% since 2005 and is using 100% renewable energy in its Elk Grove, Cork, and Austin facilities, reducing its Scope 1 &amp; 2 emissions.</p>
<p><b> </b>The CO<sub>2</sub>e emissions of a product or service include activities throughout its life cycle, right from extraction and processing of raw materials, production and use to end-of-life. The “Products” tabs shows the CO<sub>2</sub>e of some common products and services.</p>
<p><b> </b>The standard process to compute the footprint of a product is to map the supply chain, identify key activities in the product life cycle and compute emissions. This analysis will identify carbon “hotspots” in the supply chain so that appropriate actions can be taken to reduce emissions in those activities. The iPhone5 for example (see the “Product breakdown” tab) 76% of the 75 kg of CO<sub>2</sub>e emissions are from its production, 18% from customer use; 4% from transportation, and 2% from recycling. No surprise that production is such a large part – <a href="http://www.apple.com/supplierresponsibility/our-suppliers.html">Apple’s complex and global network of suppliers and assemblers</a> contribute to it. To reduce the impact will take product redesign, engaging suppliers and customers, increasing efficiencies of processes, use of renewable energy and reclaiming products after use to create raw material.</p>
<p><b> </b><b>Final Thoughts</b></p>
<p>The IPCC reports that to stabilize carbon dioxide levels between 445 and 490 ppm, emissions would need to peak around 2015, along with a 50% to 85% reduction on 2000 levels by 2050. While the current trajectory of public policy and organizational response to sustainable development is encouraging, it falls well short of the reductions recommended to maintain CO<sub>2</sub> concentrations in the 445-490 ppm range, leaving much of humankind susceptible to the risks of climate change. Hopefully, we, as nations, local and city governments, companies and consumers of products and services, can redouble our efforts to significantly reduce our footprints. This effort needs to be focused on how we generate and use energy, increase the efficiency &#8211; both ecological and economic – of our industrial and agricultural processes, and finally, how we “close the loop” or conserve and reuse natural resources in supply chains.</p>
<p>Yes, it is time to act.</p>
<p><a href="http://www.linkedin.com/pub/malcolm-hegeman/49/590/377/">Malcolm Hegeman</a> contributed to this post and to the development of the visual.</p>
<p>&nbsp;</p>
<p><b>Notes:</b></p>
<p><b> </b>1. This post is an excerpt from my book: <a href="http://www.springer.com/business+%26+management/operations+research/book/978-1-4419-6104-4">Sustainable Supply Chains (Springer)</a></p>
<p>2. Data Sources:</p>
<p>a) GHG total for countries and per-capita emissions: Climate Analysis Indicators Tool (CAIT) Version 8.0. (Washington, DC:  World Resources Institute, 2011). Can be freely downloaded from: <a href="http://cait.wri.org">CAIT</a></p>
<p>b) Cities emission data is available from the Carbon Disclosure Project: <a href="https://www.cdproject.net/en-US/Programmes/Pages/CDP-Cities-2011.aspx">CDP Cities</a></p>
<p>c) Data for the footprints of industrial sectors were collated from the Carbon Disclosure Project: <a href="https://www.cdproject.net/en-US/Programmes/Pages/CDP-Investors.aspx">CDP Investor Program</a></p>
<p>d) Product and supply chain data are self-reported by those companies. Details are available from me.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://operationsbuzz.com/2013/06/carbonfootprints/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Day in the Life: JantaKhoj&#8217;s Tarun Bangari</title>
		<link>http://operationsbuzz.com/2012/01/tarun-bangari/</link>
		<comments>http://operationsbuzz.com/2012/01/tarun-bangari/#comments</comments>
		<pubDate>Mon, 09 Jan 2012 05:45:45 +0000</pubDate>
		<dc:creator><![CDATA[Ram Ganeshan]]></dc:creator>
				<category><![CDATA[A Day in the Life]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[services]]></category>

		<guid isPermaLink="false">http://operationsbuzz.com/?p=325</guid>
		<description><![CDATA[Tarun Bangari is Founder &#38; CEO, <a href="http://www.jantakhoj.com">JantaKhoj InfoServices Pvt Ltd</a>.  JantaKhoj (translates to “people search” in Hindi) provides the first and the largest people search portal in India, offering people search and background check services to businesses and individuals.

He talks about how JantaKhoj got started, challenges he faces, and his typical workday.
]]></description>
				<content:encoded><![CDATA[<p>Tarun Bangari is Founder &amp; CEO, <a href="http://www.jantakhoj.com">JantaKhoj InfoServices Pvt Ltd</a>.  JantaKhoj (translates to “people search” in Hindi) provides the first and the largest people search portal in India, offering people search and background check services to businesses and individuals.</p>
<p>He talks about how JantaKhoj got started, challenges he faces, and his typical workday.</p>
<p>In addition to his CEO role, Tarun also manages product management, marketing and sales. Prior to founding JantaKhoj, Tarun has worked in various leadership roles in software development, consulting, product management, sales, and marketing. Tarun has PGDM/MBA from Indian Institute of Management Calcutta and B.Tech from IIT-BHU Varanasi.</p>
<p><strong>Q</strong>: How did JantaKhoj get started? What is your value proposition to your clients?</p>
<p>In early 2009, I had just quit my earlier job as Vice President of Sales &amp; Marketing at netXccel and was debating whether I should reenter the job market or try my hand at entrepreneurship. I connected with Ajit Gupta, a serial entrepreneur and ex-CEO of Speedera, where I had been a product manager. We looked at various business ideas and eventually narrowed down on people search and background verifications portal. This was an underserved area in India and we thought we can create something new and exciting. We did further market analysis and eventually incubated the start-up in June 2009, after expanding the team with Head-Engineering and Head-Verifications.</p>
<p>We provide the first and the largest people search portal on Indians, covering more than 500 million individuals, that is around 40% of the entire Indian population. Additionally, we aim to provide more detailed background checks, using online and offline approaches, to individuals and businesses, at a reasonable price.</p>
<p><strong>Q</strong>: What are the major challenges of verifying someone’s identity and background in India?</p>
<p>The biggest challenge historically has been the lack of centralized databases for identity and background checks. The ambitious, Aadhar Project (<a href="http://uidai.gov.in/">National UID Project of India</a>) which is already in the roll-out stage, aims to provide a comprehensive one stop shop for verifying identity. There are two more projects (Home ministry sponsored <a href="http://ncrb.nic.in/cctns.htm">Crime and Criminal Tracking Network &amp; Systems</a> and Education ministry led <a href="https://www.nad.co.in/AboutUs.seam">National Academic Depository</a>) which aim to create nationwide centralized databases for all police records and education certificates respectively. Till the time, these initiatives are fully rolled out, we have to rely on physical trips to police offices and universities to check the records. Additionally, address checks will still require a physical trip. Employment and reference checks still need to be done through phone, email or a site visit.</p>
<p><strong>Q</strong>: What are the operational challenges of physical lookups? Do you need contract workers all over India that do it for you? Do you have multiple layers of verification?</p>
<p>The sheer size of India presents great operational challenges in physical lookups. It is economically unviable for a single entity to have its own workers all over the country. So we have a set of trusted vendors who help us in expanding our physical reach. We do not have multiple layers of verification as such, but periodically we do audits and counter-checks to ensure that the quality and reliability of checks remains impeccable.</p>
<p><strong>Q:</strong> How is being an entrepreneur in India different from the US where you have worked before?</p>
<p>This will not be a fair comparison as when I was in US, I was working as an employee with H1-B visa in a consulting firm. So my options were somewhat limited and also at that point of time, even though earlier I had done my MBA from IIM Calcutta, I still had very little marketing and sales experience. After the US stint, I joined Speedera Networks as a product manager in their Bangalore center and continued working in the area of marketing even after Akamai acquired Speedera. This gave me a deep understanding of marketing, pre-sales, customer interactions and Internet based industries. And over these years, India has continued to emerge as a great opportunity for first time entrepreneurs like me. More and more folks are now considering entrepreneurship as a calling and these are indeed very exciting times!</p>
<p><strong>Q:</strong> Any words of advice for budding entrepreneurs in India?</p>
<p>Being a first time entrepreneur, I think I cannot hand out any ‘advice’ to budding entrepreneurs as I myself am learning every day. A few points for consideration would be:</p>
<ul>
<li>Ensure that you have some financial cover personally. You may not see salary or surplus cash for quite some time!</li>
<li>Don’t be afraid. Take the jump. The journey is worth it irrespective of eventual success or failure. Either way, you will learn infinitely more than in a regular job.</li>
<li>Validate your business ideas sooner than later. Learn fast from market. Change course faster.</li>
<li>Try to hit positive cash flow as soon as possible. In fact, one of the strategic advisors of JantaKhoj went to the extent of recommending being cash flow positive right from Day 1 of the business (unfortunately, we were not able to meet his advice)!</li>
</ul>
<p><strong>A day in the life</strong>:</p>
<p><strong>6:30</strong> &#8211;  My four and a half year old son is our ‘natural’ alarm clock. The day begins when he moves in to our bedroom in the morning and shares a few minutes of cuddling with me and my wife. As I help in getting him ready for the school, I quickly check the emails and messages on my smartphone. Online order confirmation emails are always a pleasure to see right in the morning. I also keep an eye on any customer service related emails which I need to escalate to either engineering or customer service team members.</p>
<p><strong>7:30</strong> &#8211; After having my son board his school bus, I am out for around one hour of morning exercise (outdoor brisk walking or swimming on alternate days). Invariably my thoughts meander around various aspects of the business – how is the working capital situation, how is the website traffic doing, how to close a particularly large B2B deal, is the PPC campaign really holding up well, is the Facebook presence helping with B2B prospects too?</p>
<p><strong>9:45</strong> &#8211; I drive over and reach my office. A few of the team members are already in. If there is any significant update, they will share it immediately with me. But on most days, I settle down and update/review the task list for the day. Next I review the emails in detail and try to respond to them or forward them to suitable owners with team. I do some other quick and regular checks – Google Analytics for website traffic stats, AdWords campaigns progress, AdSense earnings, our Facebook page, company’s Twitter account, CRM dashboard for any alerts/reminders. More importantly, I check the offline chat messages which may have come in overnight and either respond to them myself or forward to the suitable owner within team. I try to close the most important tasks/action items in the pre-lunch part of the day. While I cannot fully control the time for customer meetings, still to the extent possible, I try to schedule them in the first half of the day – the earlier slots work best.</p>
<p><strong>1:00</strong> &#8211; I prefer to take packed lunch from home as it turns out to be more healthy and time-saving. I have my lunch with my core team and more often than not, we continue discussing and brainstorming over lunch. Post lunch, I may take a stroll to our bank branch to submit customer payment cheques or any other required paperwork.</p>
<p><strong>2:00</strong> – I review the various marketing campaigns and B2B sales pipeline. Every couple of days, I have one-on-one discussions with my sales team members to do a pipeline and leads review, and to see what we can do to accelerate these deals further.</p>
<p><strong>4:00</strong> – I may have a discussion with the engineering team to see how our new initiatives and existing upgrades are going on. Else I may keep on working on customer service issues and interacting with Verifications team to check the status of various verification cases.</p>
<p><strong>6:30</strong> – I head back home. After changing and settling down, I spend some time catching up with my wife and with my son, either watching/helping him draw or just watching cartoons on TV.</p>
<p><strong>7:30</strong> – We generally have an early dinner, after which I clean up and load the dishwasher. I then put my son to bed at around 8:30 while reading a story (or occasionally a ‘story-a-thon’ if we have extra time!)</p>
<p><strong>9:00</strong> – My wife and I go out for a brief stroll in which we exchange detailed daily notes and other interesting news items from work or otherwise. We watch the TV for some time.</p>
<p><strong>10:00</strong> – Quite often, I come back to my laptop for a final daily summary session – evaluating how the day went off for JantaKhoj, what we can do better tomorrow. Occasionally, I use this slot to do further web-based research on specific topics, markets, competitors.</p>
<p><strong>About JantaKhoj</strong></p>
<p>JantaKhoj (translates to “people search” in Hindi) provides the first and the largest people search portal in India, offering people search and background check services to businesses and individuals.</p>
<p>Its tagline, ‘Search People, Research Background’, precisely describes its areas of service. JantaKhoj provides employee background verification services that enable businesses to verify credentials including address, references, education, employment and criminal history. JantaKhoj also enables people to conduct matrimonial, tenant, driver and domestic help verification among others. </p>
]]></content:encoded>
			<wfw:commentRss>http://operationsbuzz.com/2012/01/tarun-bangari/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>In Conversation: Human Genome Sciences&#8217; H. Thomas Watkins</title>
		<link>http://operationsbuzz.com/2011/05/thomas-watkins/</link>
		<comments>http://operationsbuzz.com/2011/05/thomas-watkins/#comments</comments>
		<pubDate>Sat, 14 May 2011 14:12:16 +0000</pubDate>
		<dc:creator><![CDATA[Ram Ganeshan]]></dc:creator>
				<category><![CDATA[Thought Leadership]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Life Sciences]]></category>

		<guid isPermaLink="false">http://operationsbuzz.com/?p=307</guid>
		<description><![CDATA[H. Thomas Watkins is the CEO of Human Genome Sciences Inc. HGS exists to place new therapies into the hands of those battling serious disease. On March 9, 2011, the FDA approved BENLYSTA, a specialized drug to treat Lupus.

<p>He talks about leadership and operational challenges of becoming a fully commercial biopharmaceutical company.

<p>Read and Enjoy!]]></description>
				<content:encoded><![CDATA[<p>H. Thomas Watkins is the CEO of Human Genome Sciences Inc (HGS). HGS exists to place new therapies into the hands of those battling serious disease. On March 9, 2011, the FDA approved BENLYSTA, a specialized drug to treat Lupus.</p>
<p>He talks about leadership and operational challenges of becoming a fully commercial biopharmaceutical company.</p>
<p>Read and Enjoy!</p>
<p><strong>About Tom Watkins</strong></p>
<p>H. Thomas Watkins joined <a href="http://www.hgsi.com/">HGS</a> as Chief Executive Officer and a Director in December 2004, and was also named President in December 2005. Mr. Watkins came to HGS with nearly twenty years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. He joined Abbott in 1985 and held various executive positions in the Pharmaceutical Products Division, Diagnostics Division and Health Systems Division prior to serving as President of TAP Pharmaceutical Products, Inc., from 1998 to 2004. Mr. Watkins began his career in 1974 with Arthur Andersen &amp; Co., and was a management consultant with McKinsey and Company, Inc., from 1979 to 1985. Mr. Watkins holds a bachelor’s degree from the College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. He is a member of the Board of Directors of Vanda Pharmaceuticals, Inc., the Biotechnology Industry Organization (BIO), the U.S. Chamber of Commerce, and the National Symphony Orchestra. Mr. Watkins currently serves as Chair of the Life Sciences Advisory Board of the State of Maryland.</p>
<p>Following is a condensed version of <a href="http://mason.wm.edu/faculty/ganeshan_r/">Professor Ram Ganeshan’s</a> (RG) conversation with Tom Watkins (TW).</p>
<p>RG: Can you tell us how the Business Model at HGS has evolved over the years?</p>
<p>TW: HGS founded in 1992 and went public in 1993. I’ve been with the company since 2004. The business model we were following in the late nineties was research and discovery of drug candidates based on genomic discovery techniques. The idea was to do a Phase I clinical trial and then potentially out-license this large body of drugs to a number of companies, partner to develop them.</p>
<p>RG: You are now…</p>
<p>TW: We are now a classic biologics drug developer, manufacturer, and commercialization company. Pretty much got out of the research, the raw discovery business.</p>
<p>Biotech companies have found, since the market crashed in 2000-01, that if you start in the research or discovery end of the business and forward integrate into development, manufacturing, and commercialization, you are going to run out of money. So you have got to make some choices. We found that we had to wind down or significantly cut back the research operation with the objective of taking a few drug candidates all the way through clinical trials to commercialization to see if we could get anything on the market.</p>
<p>We had at one time, 400 people in research in the company. Now we have about 50.</p>
<p>We now have a strong development group that manages the clinical studies for the drugs through Phase I, Phase II, and Phase III. Over the years we’ve shifted the skill set from early stage research to the later stages of drug development and manufacturing. So I’d say the core strengths of the company are clinical development, manufacturing, and increasingly commercialization. We just built our first sales force in the last in 6 or 7 months for marketing the lupus drug BENLYSTA. We’ll actually co-market it with <a href="http://www.gsk.com/">Glaxo Smith Kline (GSK)</a> &#8212; they’ll handle about half of the commercialization in the US.</p>
<p>RG: You co-market BENLYSTA with GSK – how is that working?</p>
<p>TW: I think it is working pretty well. The challenge is marketing a specialty drug – a new one in over 60 years &#8212; that&#8217;s going to rheumatologists to treat a particular condition, Lupus. Although GSK has big commercial resources, in this particular area &#8212; rheumatology &#8212; they are limited. I think the nature of the challenge is to leverage their experience in areas that they already know well, like selling to manage care, while we are both learning how to call on doctors in this particular area.</p>
<p>Until recently we have never manufactured to commercial standards. GSK does not have a big biologics commercial manufacturing organization. Its relatively small, they do a lot of small molecule pill, tablet, and capsule manufacturing, so we feel like we’re pretty good there. In Europe, why are we building an organization in three countries when they’ve already got it? More of a strategic reason &#8212; our company will hopefully have products beyond this one and this partnership allows us to get a little of a foothold in those countries.</p>
<p>RG: Tell us a little bit about your supply chain…</p>
<p>TW: Biologic drugs are living cells. They are either IV’s or injectable, you cannot put them in a capsule or a pill. We make the bulk drug which comes out as a powder, send it off to a contract manufacturer in Kansas that does a fill finish which is pretty standard in our industry. And then they send it to a distribution channel some of which Glaxo Smith Kline (GSK) runs.</p>
<p>RG: So the bulk drug is the end product for you?</p>
<p>TW: the bulk drug is the end product for us.</p>
<p>RG: Meaning you actually sell that bulk drug before it’s packaged?</p>
<p>TW: No we transfer, the contract manufacturer does it under our control. They package it and we still own the inventory and then we sell it to the distribution chain. It is not technically sold until it goes to a wholesaler or distributor. So even going into the GSK warehouse it is still under our general control.</p>
<p>RG: Your commercial organization then creates the demand?</p>
<p>TW: We would distribute through the distributor or a specialized wholesaler. These are drugs that are infused in the doctor’s office. So our reps are going to a rheumatologist, creating the need and then they order it from the special wholesaler.</p>
<p>RG: What about the supply side, how do you get your raw materials?</p>
<p>TW: Commercial suppliers of media and other components manage all that.</p>
<p>TW: So your core competence would be the process to make the drug.</p>
<p>TW: Yes. Our process development organization works closely with the manufacturing to make sure the process is optimized, consistent and that proper procedures are followed.</p>
<p>RG: What is the biggest challenge operationally? How would you go from discovering a new drug to mass-producing it?</p>
<p>TW: Two things, you have to ramp up the quantities that you are making. During clinical trials the doses are small, maybe 1600 liters. The manufacturing scale we are making now is 20,000 liters, so you have to scale it up and make sure yields remain very high.</p>
<p>Second, we have to be consistent &#8212; because a batch of 20,000 liters, costs you a million dollars, you cannot lose a batch. Since the plant has to be inspected by the FDA and they look at all process records, you can’t tweak the process during the course of manufacturing.</p>
<p>RG: How do you match supply and demand?</p>
<p>TW: The cycle time for a single batch is 6 months. For BENLYSTA, we got results from the final clinical trials in July of 2009 and November of 2009. In July 2009, it was very clear that the drug was going to be successful. So we started manufacturing it 24/7 &#8212; took our facility and ramped it up to 3 shifts. And that was in August and September of 2009, 18 months before we were selling the product. So we took risks there. The second thing we did last July, recognizing how big the demand was likely to be, we went out and signed with a major contract supplier so we would have back up capacity by the middle of 2012.</p>
<p>RG: Can this product be in inventory?</p>
<p>TW: Yes, it has a shelf life of several years at the bulk stage. Once you fill it goes down a little bit. But it is a pretty long life.</p>
<p>RG: So the risk of making too much is you just hold it.</p>
<p>TW: Right.</p>
<p>RG: How do you decide on the portfolio of drugs?</p>
<p>TW: It is an interesting but not always perfect process. We go through a regular portfolio review of, at all stages, drugs that are pre-clinical where we haven’t put them into human trials.</p>
<p>Back in the nineties, back in our early research days, we found and discovered many genomic targets which are little pieces of cell matter that appear to be implicated in some disease process, usually cancer or immunology. Back in 2005 when we slowed down the research area a lot of those targets were put in the freezer and we stopped the work. In 2008, we’ve gone back on a limited basis and identified about 50 of those we’d like to develop further. So we have got a group of 50 and we are going down sequentially the ones we think are the highest priority. That’s way early in the process. Those will not be drugs on the market until 2020. There are other drug candidates that are in Phase I or Phase II clinical trials that we just keep monitoring. When we get to the end of a trial and the data looks good, we take it to the next stage. If it does not, we kill it.</p>
<p>You have to figure out a low risk, low cost way to go to the next level. We don’t just look at them internally; we put them through rigorous peer reviews on the outside. We’ll empower a group of scientific experts in a particular therapeutic class, call them expert panels, bring them in for 2 days to scrutinize the data to see if it is worth moving forward. We’ll go to our Board with a number of scientific experts and they’ll chew it over. So the decision to go to the next phase of development is a big decision. You sort of bet the company.</p>
<p>The other major drug program we had when the Lupus drug was coming along, was called Zalbin. It was a Hepatitis C drug we got through Phase III and submitted it to the FDA and it never got approved. So we spent hundreds of millions of dollars on it.</p>
<p>RG: So they didn’t like the results?</p>
<p>TW: Yes, there was concern. You have to prove two things in clinical trials. You have to prove that the drug is effective and safe. And it’s a tradeoff. The higher the efficacy the more likely it will have side effects. On the other hand, the lower the efficacy is, relative to existing therapies, you better have an excellent safety profile. This drug had good efficacy, not that much better than what was out there, but the FDA had concerns that there were some pulmonary side effects. They were not willing to put it on the market. And that is the tradeoff they have to make. We disagree but at the end of the day we decided it’s not worth investing more. So it’s a very high-risk business, at every stage of the process your costs go up roughly by an order of magnitude. For this lupus drug we spent $300 million dollars in just the last phase of development between 2006 and 2009 and GSK spent the same amount. So $600 million was spent just in the last three years. The motto in our business is if you’re going to kill a program, kill it early. And the temptation of everybody in the science, in our company, any company, is to do one more trial…</p>
<p>RG: But by the time you spent the 300 million dollars, you knew it was going to be a success, right?</p>
<p>TW: Well, for the lupus drug, Wall Street thought it had a very low likelihood of success because we failed to reach the endpoint of Phase II trials and because no other lupus drug had been successful for a long time. The only reason they let us do it was because the Hepatitis C program sitting next to it was viewed as highly likely. It turned out to be exactly the opposite. So you don’t always know, you have to make risk decisions with the best information you have. Our logic was, we took these two programs into Phase III, they’d been there about a year, and we said we’re betting the company on these two programs. If one of them succeeds we’ll be fine, highly successful. If neither one them succeeds, we’ll have to reboot the company around something different.</p>
<p>RG: That’s what I was thinking, it’s almost like you’re betting the company.</p>
<p>TW: But that is what you do in the business when you’re starting, which we were. You have a lot of cash but you’re betting. We had to shut down a lot of little programs to bet on a few. So it is a very interesting, high-risk business. People always ask why do drugs cost so much? And I say two things they don’t want to hear: you put investor capital at very high risk in this business, so when you succeed your investors expect to be paid back at high returns. And the second is it takes hundreds of millions of dollars and 10,12, 15 years to get a drug from the beginning to the end.</p>
<p>RG: What has been your biggest leadership challenge?</p>
<p>TW: When I got to HGS, it was transforming from being basically an extremely high quality science company to a business. Projects were funded on the basis on science and not on revenue potential. So we killed many projects &#8212; really good science &#8212; but it wasn’t clear we could make any money on them. And that was sort of cold water on an organization that had really developed good capabilities. So my first year and half of the company you either loved what we were doing or your hated it depending on where you came from. Our turnover hit 35%. About half the senior management team changed and so did three quarters of the board, but that’s what we knew we had to do.</p>
<p>Then when clinical results started coming out it was managing Wall Street’s perception. We were a $10 dollar stock priced company for a couple of years then we went to $0.52 at one point, then we went to $20, now we are about $28 a share. So the challenge was to manage these enormous swings in the perception of what the company’s prospects were, in a fairly short amount of time. This was all overlaid with the financial crisis at about the same time. It was hard to keep the team together, it was hard to keep employees focused and tell Wall Street that we were on track.</p>
<p>The challenge recently has been managing down the euphoria, because BENLYSTA since 2009 has been perceived to be an enormous drug. And then your team starts to worry that expectations are so high that we can’t make any mistakes. And no team performs well when they’re that way. You got to say relax, do your best; we’re going to have some results that are not perfect. So there’s been a lot to keep us busy. But it’s fun, it’s exciting people, it’s innovation. I think keeping your heads about you the whole time is the most important thing, keeping a balance, not going off the deep end.</p>
<p><strong>About Human Genome Sciences, Inc</strong></p>
<p><a href="http://www.hgsi.com/">Human Genome Sciences, Inc</a>. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Their lead products in development are BENLYSTA (belimumab) for systemic lupus erythematosus (“SLE”) and raxibacumab for inhalation anthrax.</p>
<p>Contact: Ram.Ganeshan[at]mason.wm.edu or <a href="http://twitter.com/#!/RamGaneshan">RamGaneshan</a> on Twitter.</p>
]]></content:encoded>
			<wfw:commentRss>http://operationsbuzz.com/2011/05/thomas-watkins/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Does Filling up a Plane make the Airline Money?</title>
		<link>http://operationsbuzz.com/2011/01/airline-economics/</link>
		<comments>http://operationsbuzz.com/2011/01/airline-economics/#comments</comments>
		<pubDate>Wed, 19 Jan 2011 03:14:31 +0000</pubDate>
		<dc:creator><![CDATA[Ram Ganeshan]]></dc:creator>
				<category><![CDATA[Field Notes]]></category>
		<category><![CDATA[Airline]]></category>
		<category><![CDATA[Productivity]]></category>
		<category><![CDATA[visual]]></category>

		<guid isPermaLink="false">http://operationsbuzz.com/?p=288</guid>
		<description><![CDATA[I recently flew <a href="http://www.southwest.com/">Southwest</a> from Baltimore to LaGuardia to meet up with a few friends in Queens, NY (the little less than the $100 for a one-way fare was cheaper, and the 40-minute flight faster than the <a href ="http://www.acela.com/">Acela</a>). The flight was barely half full.  I was convinced Southwest was losing money on this flight especially with the cabin seemingly full of tourists likely paying “web only” $100 fares like myself. Really? What my research uncovered surprised me.

How much does it cost the world’s major airlines to fly a passenger a mile? How much money do they make from that passenger? How full are their planes? Read on…
]]></description>
				<content:encoded><![CDATA[<p>I recently flew <a href="http://www.southwest.com/">Southwest</a> from Baltimore to LaGuardia to meet up with a few friends in Queens, NY (the little less than the $100 for a one-way fare was cheaper, and the 40-minute flight faster than the <a href ="http://www.acela.com/">Acela</a>). The flight was barely half full. I was convinced Southwest was losing money on this flight especially with the cabin seemingly full of tourists likely paying “web only” $100 fares like myself. Really? What my research uncovered surprised me.</p>
<p>How much does it cost the world’s major airlines to fly a passenger a mile? How much money do they make from that passenger? How full are their planes? Read on…</p>
<p><strong>A little primer on airline economics.</strong></p>
<p><strong>Available Seat Miles (ASM)</strong>: It is simply the number of seats multiplied by the distance they travel. So in a sense this is the capacity of the airline. The ASM on Southwest’s 137-seat Boeing 737 aircraft from Baltimore (BWI) to LaGuardia (LGA) – a 185-mile distance – is 137 x 185  = 25,345 seat-miles.</p>
<p><strong>Revenue Passenger Miles (RPM)</strong>: It is the number of passengers multiplied by the distance. For the BWI-LGA leg above if 100 people traveled on the leg, then the RPM for the flight is 100 x 185 = 18,500 passenger miles.</p>
<p><strong>Load Factor</strong>: It is the ratio of RPM to ASM – on average tells you how “full” the planes are. For the BWI-LGA leg example above, the load factor is 18,500/25,345 = 72.9%.</p>
<p>Airlines typically report these operating numbers on a yearly basis. Southwest in 2009 had a capacity of 98,001.55 million seat-miles and a RPM of 74,456.71 million passenger miles, yielding a load factor of 76%.</p>
<p>The following graphic plots the profit/loss of the airline against the load-factor (See Note 1).  Its interactive – mouse over/click on the graph to learn more.</p>
<p>…more text after the graphic</p>
<p><script type="text/javascript" src="http://public.tableausoftware.com/javascripts/api/viz_v1.js"></script><object class="tableauViz" width="720" height="719" style="display:none;"><param name="name" value="airlineproductivityblog/Dashboard1" /><param name="toolbar" value="yes" /><param name="tabs" value="no" /></object><noscript>Dashboard 1 <br /><a href="#"><img alt="Dashboard 1 " src="http://public.tableausoftware.com/static/images/ai/airlineproductivityblog/Dashboard1/1_rss.png" height="100%" /></a></noscript></p>
<div style="width:654px;height:22px;padding:0px 10px 0px 0px; color:black;font:normal 8pt verdana,helvetica,arial,sans-serif;">
<div style="float:right; padding-right:8px;"><a href="http://www.tableausoftware.com/public?ref=http://public.tableausoftware.com/views/airlineproductivityblog/Dashboard1" target="_blank">Powered by Tableau</a></div>
</div>
<p>Surprise! Surprise! Seems like airlines are equally likely to make a profit or a loss even if they are flying with high load factors. One way to think about this is to compute the cost and revenue of moving a seat a mile. The Cost per ASM (CASM) is simply the operating costs divided by the total ASM. Total Revenue per ASM (TRASM or RASM) is the revenue of moving a seat a mile – the total revenue divided by the total ASM. If TRASM is greater than CASM, the airline is making money moving a seat a mile. The graphic above also shows the TRASM and CASM of some of the major airlines in the world. “The Gap” is the difference between the TRASM and the CASM. If it is negative, the airline is making a loss.</p>
<p><strong>Filling the gap</strong></p>
<p>For a given route network, increasing revenue comes down to increasing RPM (or load factor) and increasing “passenger yield” or the revenue per RPM (See Note 2). Easier said than done – it involves the difficult task of managing the complex relationship between price, demand, capacity (ASM), and customer ticket-buying behavior. For example, on the BWI-LGA flight, the lowest price  (three weeks out) I could find on Southwest 5015 was a “Wanna Get Away” fare of $64, or about 34.59 cents to a mile. Southwest spends 10.29 cents a mile to move a seat so they are making 24.30 cents a mile even on a passenger paying the lowest fare. Even if everybody on the plane paid $64, they only have to fill a third of the plane to breakeven.  With many of its passengers paying the $178 “Anytime” fare and the $193 “Business Select” fare, an average 76% full flight is doing very well.</p>
<p>On the other hand, the cheapest fare on Southwest 3701 from Providence (PVD) to Las Vegas (LAV), a distance of 2363 miles, was $169 or 7.15 cents a mile. Southwest is actually losing 3.13 cents on each mile this passenger travels.  Even on a full flight, Southwest needs one in three passengers to pay the  $469 “Anytime” fare or the $493 “Business Select” fare just to breakeven. So managing yield is a delicate dance between passenger demand, how much passengers are paying, how far they are travelling, and how full the aircraft is.</p>
<p>The other side of the profit equation is cost containment. The airline business has high fixed costs – you have to lease planes, secure landing rights, pay the crew, etc. Revenue is generated only when planes are in the air so the strategy to reduce the cost per seat mile is to run a “lean” and efficient airline without compromising service or safety. <a href="http://www.allegiantair.com/">Allegiant Air’s</a> cheap but profitable strategy is to run infrequent flights from small towns to big tourist destinations in easy to maintain MD-80 aircraft. Southwest’s <a href="http://www.denverpost.com/news/ci_16175981">quick turnaround times</a> – as much as 30 minutes faster than other airlines –saves them from leasing extra planes (See Note 3). We have all seen the self-check kiosks, vanishing leg-room (=more seats), and the lack of food service even on certain long-haul flights &#8212; all trying to bring down CASM.</p>
<p>Next time you fly, find out how much you are paying per mile and compare it how much it costs the airline to fly you a mile to see if you have got yourself a deal. My $100 flight from BWI-LGA was not much of a deal was it? That $169 fare on Southwest 3701 – a killer deal, I’d say.</p>
<p>Contact: Ram Ganeshan via ram.ganeshan[at]mason.wm.edu or @RamGaneshan on Twitter</p>
<p><a href="http://www.linkedin.com/pub/shoumya-pradhan/14/422/553">Shoumya Pradhan</a> contributed to research for this post.</p>
<p><strong>Notes:</strong></p>
<p>1. Data Sources: Company 10K, 20F, Annual reports; <a href="http://www.bts.gov">BTS</a>; <a href="http://www.atwonline.com">World Airline Report</a>. Data is from 2009.</p>
<p>2. In addition to increasing traffic (RPM) and managing yield, there are other – often maligned &#8212; revenue streams called “ancillary fees” like change of reservation or baggage fees (<a href="http://blogs.star-telegram.com/sky_talk/2010/09/airlines-rake-in-21-billion-in-ancillary-fees-in-second-quarter-bts-says.html">Delta raked in $681 million</a> in fees just in the 2<sup>nd</sup> Quarter of 2010!) that will increase the revenue per passenger on any flight.</p>
<p>3. In 2009, Southwest had 2546 turnarounds everyday. 30 minutes saved on one of them is 1723 hours of extra flight time per day compared to other “legacy” airlines. Means fewer planes, more money.</p>
]]></content:encoded>
			<wfw:commentRss>http://operationsbuzz.com/2011/01/airline-economics/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
	</channel>
</rss>
